ATNM
Actinium Pharmaceuticals Inc (ATNM)
Healthcare • NYSE MKT • $1.31+7.38%
- Symbol
- ATNM
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.31
- Daily Change
- +7.38%
- Market Cap
- $41.10M
- Trailing P/E
- N/A
- Forward P/E
- -2.33
- 52W High
- $1.95
- 52W Low
- $0.95
- Analyst Target
- $5.00
- Dividend Yield
- N/A
- Beta
- -0.11
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Fur…
Company websiteResearch ATNM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.